Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase
(CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer.
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
p27(KIP1) is a member of the CIP1/KIP1 family of cyclin-dependent kinase
inhibitors and is a potential tumor suppressor gene.
Cyclin D1 regulates G1 phase progression via cyclin-dependent kinase
4/6-dependent phosphorylation and partial inactivation of the repressive activity of the retinoblastoma protein.
Phase II Study of the Cyclin-Dependent Kinase
(CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias" (Abstract # 3287, Poster board #: III-66)
This is due to the fact that tumor cells frequently lose the endogenous inhibitors of cyclin-dependent kinases
The anti-tumor agent, currently in Phase I/II testing, targets cyclin-dependent kinases
(CDK) that are involved in crucial cellular functions such as tumor cell proliferation and survival signaling.
The transition through G1 to S phase is regulated by cyclins, cyclin-dependent kinases
(CDK)-CDK4 and CDK6 and their inhibitors.
Cyclins and cyclin-dependent kinases
play an important role in regulation of the cell cycle (Sherr 1996).
Sample topics include centrosomes in checkpoint responses, DNA damage response and the balance between cell survival and cell death, and targeting cyclin-dependent kinases
with small molecule inhibitors.
Inhibitors of mammalian G1 cyclin-dependent kinases